# Enliven Therapeutics, Inc.: overview

ELVN · Nasdaq · CIK 1672619 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/elvn.md) · [Financials](/companies/elvn/financials.md) · [Filings](/companies/elvn/filings.md) · [Insiders](/companies/elvn/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.48)](/filings/0001193125-25-277619.md) | not reported | [(0.57)](/filings/0001193125-26-211982.md) | [(0.49)](/filings/0001193125-26-335155.md) | [(0.32)](/filings/0001193125-25-277619.md) | not reported | [(0.38)](/filings/0001193125-26-211982.md) | [(0.49)](/filings/0001193125-26-335155.md) |
| Free cash flow | $m | [(12.2) d](/filings/0001193125-25-277619.md) | [(17.2) d](/filings/0001193125-26-088232.md) | [(24.1)](/filings/0001193125-26-211982.md) | [(17.2) d](/filings/0001193125-26-335155.md) | [(13.3) d](/filings/0001193125-25-277619.md) | [(15.8) d](/filings/0001193125-26-088232.md) | [(19.3)](/filings/0001193125-26-211982.md) | [(18.6) d](/filings/0001193125-26-335155.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(2.37)](/filings/0001564590-23-001729.md) | [(12.05)](/filings/0000950170-24-031495.md) | [(2.01)](/filings/0000950170-25-038758.md) | [(1.89)](/filings/0001193125-26-088232.md) | [(1.83)](/filings/0001193125-26-088232.md) |
| Free cash flow | $m | [(46.8)](/filings/0001564590-23-001729.md) | [(32.7)](/filings/0000950170-24-031495.md) | [(61.4)](/filings/0000950170-25-038758.md) | [(73.2)](/filings/0001193125-26-088232.md) | [(70.5)](/filings/0001193125-26-088232.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/elvn/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2020-03-16 | [Pfizer Inc](/insiders/78003.md) | 10% owner | Purchase (P) | 312,500 | $16.00 | $5.0m | [Form 4](/filings/0000078003-20-000023.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $508.8m | 10,025,017 |  | Added +3,195,771 |
| [ORBIMED ADVISORS LLC](/funds/1055951.md) | 2026-06-30 | $343.9m | 6,776,632 |  | Reduced −1,182,906 |
| [Polar Capital Holdings Plc](/funds/1837309.md) | 2026-06-30 | $326.4m | 6,430,636 |  | Added +1,364,703 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $221.3m | 4,359,704 |  | Added +674,997 |
| [Vestal Point Capital, LP](/funds/1974915.md) | 2026-06-30 | $203.0m | 4,000,000 |  | Added +750,000 |
| [Commodore Capital LP](/funds/1831942.md) | 2026-06-30 | $166.2m | 3,275,000 |  | Unchanged |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $130.4m | 2,569,002 |  | Added +400,840 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $105.0m | 2,068,992 |  | Added +325,077 |
| [Fairmount Funds Management LLC](/funds/1802528.md) | 2026-06-30 | $94.2m | 1,855,644 |  | Unchanged |
| [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $90.1m | 1,774,411 |  | Added +1,028,185 |

## Recent filings

[All 787 filings](/companies/elvn/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-14 | 16:39 ET | [8-K](/filings/0001193125-26-421761.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-421761 |
| 2026-08-05 | 16:15 ET | [10-Q](/filings/0001193125-26-335155.md) | Quarterly report, period 2026-06-30 | 0001193125-26-335155 |
| 2026-08-05 | 16:10 ET | [8-K](/filings/0001193125-26-335101.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-335101 |
| 2026-06-24 | 19:15 ET | [SCHEDULE 13D/A](/filings/0000947871-26-000651.md) | Ownership report, active investor, amended | 0000947871-26-000651 |
| 2026-06-17 | 19:41 ET | [SCHEDULE 13D/A](/filings/0000947871-26-000636.md) | Ownership report, active investor, amended | 0000947871-26-000636 |
| 2026-06-12 | 16:55 ET | [8-K](/filings/0001193125-26-269635.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-269635 |
| 2026-06-11 | 08:09 ET | [8-K](/filings/0001193125-26-266731.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-266731 |
| 2026-06-10 | 17:32 ET | [8-K](/filings/0001193125-26-264085.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-264085 |
| 2026-05-07 | 16:17 ET | [10-Q](/filings/0001193125-26-211982.md) | Quarterly report, period 2026-03-31 | 0001193125-26-211982 |
| 2026-05-07 | 16:12 ET | [8-K](/filings/0001193125-26-211921.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-211921 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-088232.md), filed Mar 3, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1672619
- Tickers: ELVN
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Non-accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:28 ET. No prices; not investment advice.